5 курс / Инфекционные болезни / Доп. материалы / Факторы,_ассоциированные_с_фиброзом_печени,_у_пациентов
.pdf22.Williamson E.J., Walker A.J., Bhaskaran K., Bacon S., Bates C., Morton C.E., Curtis H.J., Mehrkar A., Evans D., Inglesby P., Cockburn J., McDonald H.I., MacKenna B., Tomlinson L., Douglas I.J., Rentsch C.T., Mathur R., Wong A.Y.S., Grieve R., Harrison D., Forbes H., Schultze A., Croker R., Parry J., Hester F., Harper S., Perera R., Evans S.J.W., Smeeth L., Goldacre B. Factors associated with COVID-19-related death using OpenSAFELY // Nature. 2020. Vol. 584, Is. 7821. P. 430-436. DOI: 10.1038/s41586-020-2521-4.
23.Tada T., Toyoda H., Sone Y., Yasuda S., Miyake N., Kumada T., Tanaka J. Type 2 diabetes mellitus: A risk factor for progression of liver fibrosis in middle-aged patients with non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology. 2019. Vol. 34, Is. 11. P. 2011-2018. DOI: 10.1111/jgh.14734.
24.Eslam M., Newsome P.N., Sarin S.K., Anstee Q.M., Targher G., Romero-Gomez M., ZelberSagi S., Wai-Sun Wong V., Dufour J.F., Schattenberg J.M., Kawaguchi T., Arrese M., Valenti L., Shiha G., Tiribelli C., Yki-Järvinen H., Fan J.G., Grønbæk H., Yilmaz Y., Cortez-Pinto H., Oliveira C.P., Bedossa P., Adams L.A., Zheng M.H., Fouad Y., Chan W.K., Mendez-Sanchez N., Ahn S.H., Castera L., Bugianesi E., Ratziu V., George J. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement // Journal of Hepatology. 2020. Vol. 73, Is. 1. P. 202-209. DOI: 10.1016/j.jhep.2020.03.039.
25.Ji D., Qin E., Xu J., Zhang D., Cheng G., Wang Y., Lau G. Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study // Journal of Hepatology. 2020. Vol. 73, Is. 2. P. 451-453. DOI: 10.1016/j.jhep.2020.03.044.
26.Zhou Y.J., Zheng K.I., Wang X.B., Yan H.D., Sun Q.F., Pan K.H., Wang T.Y., Ma H.L., Chen Y.P., George J., Zheng M.H. Younger patients with MAFLD are at increased risk of severe COVID-
19illness: A multicenter preliminary analysis // Journal of Hepatology. 2020. Vol. 73, Is. 3. P. 719-
721.DOI: 10.1016/j.jhep.2020.04.027.
27.Roca-Fernández A., Dennis A., Nicolls R., McGonigle J., Kelly M., Banerjee R. High liver fat associates with higher risk of developing symptomatic covid-19 infection - initial UK biobank observations // The preprint server for Health Sciences. 2020. DOI: 10.1101/2020.06.04.20122457.
28.Lopez-Mendez I., Aquino-Matus J., Gall S.M., Prieto-Nava J.D., Juarez-Hernandez E., Uribe M., Castro-Narro G. Association of liver steatosis and fibrosis with clinical outcomes in patients with SARS-CoV-2 infection (COVID-19) // Annals of Hepatology. 2021, Is. 20. P. 100271. DOI: 10.1016/j.aohep.2020.09.015.
29.Marjot T., Moon A.M., Cook J.A., Abd-Elsalam S., Aloman C., Armstrong M.J., Pose E., Brenner E.J., Cargill T., Catana M.A., Dhanasekaran R., Eshraghian A., García-Juárez I., Gill U.S., Jones P.D., Kennedy J., Marshall A., Matthews C., Mells G., Mercer C., Perumalswami P.V., Avitabile E., Qi X., Su F., Ufere N.N., Wong Y.J., Zheng M.H., Barnes E., Barritt A.S. 4th, Webb
G.J. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study // Journal of Hepatology. 2021. Vol. 74, Is. 3. P. 567-577. DOI: 10.1016/j.jhep.2020.09.024.
30.Marjot T., Buescher G., Sebode M., Barnes E., Barritt A.S. 4th, Armstrong M.J., Baldelli L., Kennedy J., Mercer C., Ozga A.K., Casar C., Schramm C.; contributing Members and Collaborators of ERN RARE-LIVER/COVID-Hep/SECURE-Cirrhosis; Moon A.M., Webb G.J., Lohse A.W. SARS-CoV-2 infection in patients with autoimmune hepatitis // Journal of Hepatology. 2021. Vol. 74, Is. 6. P. 1335-1343. DOI: 10.1016/j.jhep.2021.01.021.
31.Liu J., Wang T., Cai Q., Sun L., Huang D., Zhou G., He Q., Wang F.S., Liu L., Chen J. Longitudinal changes of liver function and hepatitis B reactivation in COVID-19 patients with preexisting chronic hepatitis B virus infection // Hepatology Research. 2020. Vol. 50, Is. 11. P. 12111221. DOI: 10.1111/hepr.13553.
32.Chen L., Huang S., Yang J., Cheng X., Shang Z., Lu H., Cheng J. Clinical characteristics in patients with SARS-CoV-2/HBV co-infection // The Journal of Viral Hepatitis. 2020. Vol. 27, Is. 12. P. 1504-1507. DOI: 10.1111/jvh.13362.
33.Yu R., Tan S., Dan Y., Lu Y., Zhang J., Tan Z., He X., Xiang X., Zhou Y., Guo Y., Deng G., Chen Y., Tan W. Effect of SARS-CoV-2 coinfection was not apparent on the dynamics of chronic hepatitis B infection // Virology Journal. 2021. Vol. 553. P. 131-134. DOI: 10.1016/j.virol.2020.11.012.
34.Driggers K.E., Sadowski B.W., Shagla Е., Kwok R.M. Care of the Hepatology Patient in the COVID
19 Era // Current Hepatology Reports. 2022. Vol. 21. P. 9-20. DOI: 10.1007/s11901-021-00581-x.
35.Cerbu B., Pantea S., Bratosin F. Vidican, I.; Turaiche, M., Frent S., Borsi E., Marincu I. Liver Impairment and Hematological Changes in Patients with Chronic Hepatitis C and COVID-19: A Retrospective Study after One Year of Pandemic // Medicina. 2021. Vol. 57, Is. 6. P. 597. DOI: 10.3390/medicina57060597.
36.Yamane D., McGivern D.R., Masaki T., Lemon S.M. Liver injury and disease pathogenesis in chronic hepatitis C // Current Topics in Microbiology and Immunology. 2013. Vol. 369. P. 263-88. DOI: 10.1007/978-3-642-27340-7_11.
37.Дудина К. Р., Царук К. А., Шутько С. А., Бокова Н. О., Ющук Н. Д. Факторы прогрессирующего течения хронического гепатита С // Лечащий врач. 2013. № 10. С. 50-55.
38.Сухорук А.А., Герасимова О.А., Эсауленко Е.В. Цирроз печени как исход хронического гепатита С // Журнал инфектологии. 2014. Т. 6, № 1. С. 67-71. DOI: 10.22625/2072-6732-2014- 6-1-67-71.
39.Пинчук Т.В., Орлова Н.В., Суранова Т.Г., Бонкало Т.И. Механизмы поражения печени
при COVID 19 // Медицинский алфавит. 2020. № 19. С. 39-46. DOI: 10.33667/2078-5631-2020-
19-39-46.
Рекомендовано к изучению сайтом МедУнивер - https://meduniver.com/
40. Lizardo-Thiebaud M., Cervantes-Alvarez E., Limon-de la Rosa N., Tejeda-Dominguez F., Palacios-Jimenez M., Méndez-Guerrero O., Delaye-Martinez M., Rodriguez-Alvarez F., RomeroMorales B., Liu W.H., Huang C.A., Kershenobich D., Navarro-Alvarez N. Direct or collateral liver damage in SARS-CoV-2–Infected patients // Seminars in Liver Disease. 2020. Vol. 40, Is. 3. P. 321– 330. DOI: 10.1055/s-0040-1715108.
41.Bajaj J.S., Garcia-Tsao G., Wong F., Biggins S.W., Kamath P.S., McGeorge S., Chew M., Pearson M., Shaw J., Kalluri A., Fagan A., Olofson A., Moini M., de la Rosa Rodriguez R., Reddy K.R. Cirrhosis Is Associated With High Mortality and Readmissions Over 90 Days Regardless of COVID-19: A Multicenter Cohort // Liver Transplantation. 2021. Vol. 27, Is. 9. P. 1343-1347. DOI: 10.1002/lt.25981.
42.Duddempudi A.T. Immunology in alcoholic liver disease // Clinical Liver Disease. 2012. Vol. 16, Is. 4. P. 687-98. DOI: 10.1016/j.cld.2012.08.003.
43.Yeoh Y.K., Zuo T., Lui G.C., Zhang F., Liu Q., Li A.Y., Chung A.C., Cheung C.P., Tso E.Y., Fung K.S., Chan V., Ling L., Joynt G., Hui D.S., Chow K.M., Ng S.S.S, Li T.C., Ng R.W., Yip T.C., Wong G.L., Chan F.K., Wong C.K., Chan P.K., Ng S.C. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19 // Gut. 2021. Vol. 70, Is. 4. P. 698-706. DOI: 10.1136/gutjnl-2020-323020.
44.Bajaj J.S. Altered Microbiota in Cirrhosis and Its Relationship to the Development of Infection // Clinical Liver Disease (Hoboken). 2019. Vol. 14, Is. 3. P. 107-111. DOI: 10.1002/cld.827.
45.Boettler T., Marjot T., Newsome P.N., Mondelli M.U., Maticic M., Cordero E., Jalan R., Moreau R., Cornberg M., Berg T. Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic // JHEP Reports. 2020. Vol. 2, Is. 5. P. 100169. DOI: 10.1016/j.jhepr.2020.100169.
46.Guan W.J., Ni Z., Hu Y., Liang W., Ou C., He J., Liu L., Shan H., Lei C., Hui D. S.C., Du B., Li L., Zeng G., Yuen K.-Y., Chen R., Tang C., Wang T., Chen P., Xiang J., Li S., Wang J., Liang Z., Peng Y., Wei L., Liu Y., Hu Y., Peng P., Wang J., Liu J., Chen Z., Li G., Zheng Z., Qiu S., Luo J., Ye C., Zhu S., Zhong N. Clinical characteristics of coronavirus disease 2019 in China // The New England Journal of Medicine. 2020. Vol. 382. P. 1708-1720. DOI: 10.1056/NEJMoa2002032.
47.Fu Y., Zhu R., Bai T., Han P., He Q., Jing M., Xiong X., Zhao X., Quan R., Chen C., Zhang Y., Tao M., Yi J., Tian D., Yan W. Clinical Features of Patients Infected With Coronavirus Disease 2019 With Elevated Liver Biochemistries: A Multicenter, Retrospective Study // Hepatology. 2021. Vol. 73, Is. 4. P. 1509-1520. DOI: 10.1002/hep.31446.
48.Singh S., Khan A. Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Among Patients With Preexisting Liver Disease in the United States: A Multicenter Research
Network Study // Gastroenterology. 2020. Vol. 159, Is. 2. P. 768-771. DOI:
10.1053/j.gastro.2020.04.064.
49.Youssef M., H Hussein M., Attia A.S., M Elshazli R., Omar M., Zora G., S Farhoud A, Elnahla A., Shihabi A., Toraih E.A., S Fawzy M., Kandil E. COVID-19 and liver dysfunction: A systematic review and meta-analysis of retrospective studies // Journal of Medical Virology. 2020. Vol. 92, Is.
10.P. 1825-1833. DOI: 10.1002/jmv.26055.
50.Xiang F., Sun J., Chen P.H., Han P., Zheng H., Cai S., Kirk G.D. Early Elevation of Fibrosis-
4Liver Fibrosis Score Is Associated With Adverse Outcomes Among Patients With Coronavirus Disease 2019 // Clinical Infectious Diseases. 2021. Vol. 73, Is. 3. P. e594-e601. DOI: 10.1093/cid/ciaa1710.
Рекомендовано к изучению сайтом МедУнивер - https://meduniver.com/